Attenuation of doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment

Hypertension

Volumn 55, Issue 3, 2010, Pages 738-746

  Miyagawa, Kazuya ^a   Emoto, Noriaki ^a,c   Widyantoro, Bambang ^a   Nakayama, Kazuhiko ^a   Yagi, Keiko ^a,c   Rikitake, Yoshiyuki ^b   Suzuki, Takashi ^d   Hirata, Ken Ichi ^a  

^a Division of Cardiovascular Medicine   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial natriuretic peptide; Cardiomyopathy; Doxorubicin; Endothelin 1; Endothelin converting enzyme 1; Mitochondria

Indexed keywords

ADENOSINE PHOSPHATE; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DOXORUBICIN; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; BLOOD LEVEL; CARDIOMYOPATHY; CELL SIZE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE EXPRESSION; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; HISTOPATHOLOGY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLE; TISSUE LEVEL; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIHYPERTENSIVE AGENTS; ASPARTIC ACID ENDOPEPTIDASES; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOMYOPATHIES; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOXORUBICIN; ECHOCARDIOGRAPHY; ENDOTHELIN-1; HEART RATE; MALE; METALLOENDOPEPTIDASES; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MYOCARDIUM; PEPTIDES, CYCLIC;

EID: 77149166959     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.141903     Document Type: Article

References (45)

1. Bristow MR BM, Mason JW, Daniels JR. Clinical spectrum of anthra-cycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978;62:873-879.
2. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49: 330-352.
3. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-777.
4. Xiong Y, Liu X, Lee CP, Chua BH, Ho YS. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic Biol Med. 2006;41:46-55.
5. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, Piantadosi CA. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest. 2007;117:3730-3741.
6. Capranico G, Tinelli S, Zunino F. Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. Chem Biol Interact. 1989;72:113-123.
7. Holm C, Stearns T, Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol. 1989;9:159-168.
8. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415. (Pubitemid 18090241)
9. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-2440.
10. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41: 851-876.
11. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485-498.
12. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr. Endothelin in human congestive heart failure. Circulation. 1994;89:1580-1586.
13. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 1997;18: 254-258.
14. Masson S, Latini R, Anand IS, Barlera S, Judd D, Salio M, Perticone F, Perini G, Tognoni G, Cohn JN. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail. 2006;12:375-380.
15. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, Stewart DJ. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation. 2004;109:255-261.
16. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473-485.
17. Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, Clouthier DE, de Wit D, Emoto N, Hammer RE. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development. 1998;125: 825-836.
18. Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, Koopman PA. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004;94: 237-239.
19. Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM. Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol. 2001;89:140-144.
20. Yuhki KI, Miyauchi T, Kakinuma Y, Murakoshi N, Maeda S, Goto K, Yamaguchi I, Suzuki T. Endothelin-1 production is enhanced by rotenone, a mitochondrial complex I inhibitor, in cultured rat cardiomyo-cytes. J Cardiovasc Pharmacol. 2001;38:850-858.
21. Johnson GD, Stevenson T, Ahn K. Hydrolysis of peptide hormones by endothelin-converting enzyme-1: a comparison with neprilysin. J Biol Chem. 1999;274:4053-4058.
22. Piantadosi CA, Suliman HB. Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1. J Biol Chem. 2006;281:324-333.
23. Tobe SS, Linacre AM. A technique for the quantification of human and non-human mammalian mitochondrial DNA copy number in forensic and other mixtures. Forensic Sci Int Genet. 2008;2:249-256.
24. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the ther-mogenic coactivator PGC-1. Cell. 1999;98:115-124.
25. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106: 847-856.
26. Piantadosi CA, Carraway MS, Babiker A, Suliman HB. Heme oxygen-ase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated tran-scriptional control of nuclear respiratory factor-1. Circ Res. 2008;103: 1232-1240.
27. Takuma K, Phuagphong P, Lee E, Mori K, Baba A, Matsuda T. Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. J Biol Chem. 2001;276:48093-48099.
28. Mitsuishi M, Miyashita K, Itoh H. cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochem Biophys Res Commun. 2008;367:840-845.
29. Boulanger C, Schini VB, Moncada S, Vanhoutte PM. Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bra-dykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide. Br J Pharmacol. 1990;101:152-156.
30. Silberbach M, Roberts CT Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal. 2001;13: 221-231.
31. Kato T, Muraski J, Chen Y, Tsujita Y, Wall J, Glembotski CC, Schaefer E, Beckerle M, Sussman MA. Atrial natriuretic peptide promotes cardio-myocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest. 2005;115:2716-2730.
32. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxo-rubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dis-mutase activity, and Bcl-2:Bax ratio. Cancer Res. 2002;62:4592-4598.
33. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, Chan WY, Zhao H, To MY, Fok TF, Li CK, Wong YO, Ng PC. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxo-rubicin. Circulation. 2006;113:2211-2220.
34. Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, Bohm M. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999;99:2118-2123.
35. Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, Staudt A, Schultheiss HP, Ewert R, Volker U, Tschope C, Kroemer HK. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007;67:10428-10435.
36. Marin-Garcia J, Goldenthal MJ, Moe GW. Selective endothelin receptor blockade reverses mitochondrial dysfunction in canine heart failure. J Card Fail. 2002;8:326-332.
37. Hystad ME, Geiran OR, Attramadal H, Spurkland A, Vege A, Simonsen S, Hall C. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand. 2001;171:395-403.
38. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decom-pensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72:1787-1793.
39. Westermann D, Lettau O, Sobirey M, Riad A, Bader M, Schultheiss HP, Tschope C. Doxorubicin cardiomyopathy-induced inflammation and apo-ptosis are attenuated by gene deletion of the kinin B1 receptor. Biol Chem. 2008;389:713-718.
40. Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A, Bader M, Schultheiss HP, Tschope C. Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes. 2009;58:1373-1381.
41. Yoshida H, Zhang JJ, Chao L, Chao J. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reper-fusion. Hypertension. 2000;35:25-31.
42. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003;285:H1479-H1488.
43. Li HJ, Yin H, Yao YY, Shen B, Bader M, Chao L, Chao J. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007;73:130-142.
44. Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angio-tensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev. 2005;23:317-330.
45. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346: 896-903. (Pubitemid 34984638)